Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Awareness and Prophylaxis Practices Reported by Patients with Cancer

REFERENCES

• US Department of Health and Human Services. The surgeon general's call to action to prevent deep vein thrombosis and pul monary embolism. 2008. http://www.surgeongeneral.gov/topics/ deepvein/
   Google Scholar
• U.S. Census Bureau News. Nation's Population to reach 300 Million on Oct. 17. U.S. Department of Commerce Public Information Office. October 12, 2006. Available at: http://www. census.gov/Press-Release/www/releases/archives/population/007 616.html. 2006.
   Google Scholar
• Anderson FA Jr.; Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–938.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452–463.
   PubMed Web of Science ®Google Scholar
• Heit JA. The epidemiology of venous thromboembolism in the community: Implications for prevention and management. J Thromb Thrombolysis 2006;21:23–29.
   PubMed Web of Science ®Google Scholar
• Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: A population-based study. Mayo Clin Proc 2000;75: 1249–1256.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.
   PubMed Web of Science ®Google Scholar
• Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160, 761–768.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445–453.
   PubMed Web of Science ®Google Scholar
• Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost 2006;4: 529–535.
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458–464.
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60–68.
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614–1615.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al., Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–815.
   PubMed Web of Science ®Google Scholar
• Kucuk O, Kwaan HC, Gunnar W, Vazquez RM. Thromboembolic complications associated with l-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 1985;55: 702–706.
   PubMed Web of Science ®Google Scholar
• Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657–1667.
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14: 2731–2737.
   PubMed Web of Science ®Google Scholar
• Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514–1520.
   PubMed Web of Science ®Google Scholar
• Khorana AA. Cancer and thrombosis: Implications of published guidelines for clinical practice. Ann Oncol 2009;20: 1619–1630.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis. 9th ed-American College of Chest Physicians evidence based clinical practice guidelines. Chest 2012;141(2s):e195S-226S.
   Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285–291.
   PubMed Web of Science ®Google Scholar
• White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782–1787.
   PubMed Web of Science ®Google Scholar
• APHA. American Public Health Association. Deep-Vein Thrombosis: Advancing awareness to protect patients lives. Public Health Leadership Conference on Deep-Vein Thrombosis. White Paper. 2003 Feb 26.
   Google Scholar
• Sousou T, Khorana AA. Cancer patients and awareness of venous thromboembolism. Can Invest 2010;28:44–45
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Rojan A, Campigotto F, et al. Pattern of frequent but non-targeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: A prospective, cross-sectional, multicenter Study. J Clin Oncol 2014;32:1792–1796.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Eikelboom JH, Gould MK, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients. Chest 2012;141:e185S-e194S.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Practice Guideline Update. J Clin Oncol 2013;31:2189–2204.
   PubMed Web of Science ®Google Scholar
• Haut ER, Lau BD. Prevention of venous thromboembolism: Brief Update Review. In: Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices. Rockville (MD): Agency for Healthcare Research and Quality, (US); 2013 (evidence Reports/Technology Assessments, No.211.) Chapter 28. Available from: http://www.ncbi. nlm.nih.gov/books/NBK133387/
   Google Scholar
• Agency for Healthcare Research and Quality. Safe Practices for Better Healthcare: A Consensus report summary. The National Quality Forum. Rockville (MD): Agency for Healthcare Research and Quality; 2003. Rockville, MD. Available from: https://innovations.ahrq.gov/qualitytools/30-safe-practices-better-health-care-fact-sheet.
   Google Scholar
• Burleigh E, Wang C, Foster D, et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 2006;63:S23–S29.
   PubMed Web of Science ®Google Scholar
• Amin A, Stemkowski S, Lin J. Thromboprophylaxis rates in US medical centers: Success or failure? J Thromb Haemost 2007;5:1610–1616.
   PubMed Web of Science ®Google Scholar
• Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007;98:656–661.
   PubMed Web of Science ®Google Scholar
• Amin AN, Stemkowski S, Lin J, Yang G. Inpatient thromboprophylaxis use in U.S. hospitals: Adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. J Hosp Med 2009;4:E15–E21
   PubMedGoogle Scholar
• Kleinjan A, Aggarwal A, Geer VD, et al. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 2013;110:959–965.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944–1948.
   PubMed Web of Science ®Google Scholar